NervGen Pharma Corp.
NGEN.V
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 35.02% | 27.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.18% | -13.50% | |||
| Operating Income | -11.18% | 13.50% | |||
| Income Before Tax | -139.19% | 55.27% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -139.19% | 55.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -139.19% | 55.27% | |||
| EBIT | -11.18% | 13.50% | |||
| EBITDA | -11.20% | 13.50% | |||
| EPS Basic | -134.96% | 55.75% | |||
| Normalized Basic EPS | -135.39% | 55.74% | |||
| EPS Diluted | -134.96% | 55.75% | |||
| Normalized Diluted EPS | -135.39% | 55.74% | |||
| Average Basic Shares Outstanding | 1.82% | 0.97% | |||
| Average Diluted Shares Outstanding | 1.82% | 0.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||